ClinicalTrials.gg
CompletedNCT04699240Updated Jun 12, 2025

Study of Lactobacillus in Adjuvant Treatment of RVVC

A Phase 4 interventional study of clotrimazole vaginal tablets and Clotrimazole vaginal tablets+ Lactobacillus in Recurrent Vulvovaginal Candidiasis, sponsored by Peking University Shenzhen Hospital. Completed at 1 site in China. Open to female participants aged 18 Years to 52 Years. Per ClinicalTrials.gov, last updated 2025-06-12.

Sponsored by Peking University Shenzhen Hospital · Phase 4, Interventional, and Treatment

From the registry’s dates

  • Registered 6 months after the study started (first participant enrolled Jul 2020, registered Jan 2021).
Phase
Phase 4
Study type
Interventional
Enrollment
140
Allocation
Randomized
Ages
18 Years to 52 Years
Sex
Female
01

Study summary

We are trying to determine if Clotrimazole vaginal tablets with oral Lactobacillus is better than Clotrimazole vaginal tablets in Preventing the Recurrence of vulvovaginalcandidiasis

Read the detailed description

vulvovaginal candidiasis is common disease in women. Its refractory and high recurrence rate has always been a clinical problem. Some cases even recur several times a year, and those who recur more than four times a year are diagnosed as recurrent vaginal candidal infection Candidiasis, RVVC)。 The common clinical regimen for VVC is to strengthen and consolidate clotrimazole vaginal tablets for up to 25 weeks. However, long-term antibiotic treatment will lead to the decrease of vaginal microflora and the disappearance of inflammation and pathogenic bacteria, which will greatly increase the probability of repeated infection and become a barrier to clinical treatment. If probiotics are added in the treatment, the abundance of lactobacillus can be ensured while antibiotic treatment is carried out, the homeostasis of reproductive tract flora can be reestablished, the defense mechanism can be improved fundamentally, and the re invasion of pathogenic bacteria can be reduced, which will become a new treatment idea and method for radical cure of refractory RVVC.

We hypothesize that Clotrimazole vaginal tablets with oral Lactobacillus is better than Clotrimazole vaginal tablets in Preventing the Recurrence of vulvovaginalcandidiasis.

02

Conditions studied

  • Recurrent Vulvovaginal Candidiasis

Keywords

  • Recurrent Vulvovaginal Candidiasis
  • Lactobacillus
  • reproductive tract flora
03

In context

Candidiasis, Vulvovaginal

109 studies on the registry are indexed under Candidiasis, Vulvovaginal; 14 are open to participants now.

This study's enrollment of 140 is above the median of 126 across 91 interventional studies indexed under Candidiasis, Vulvovaginal.

Browse Candidiasis, Vulvovaginal studies →

Lead sponsor

Peking University Shenzhen Hospital is the lead sponsor of 17 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 52 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Women be at least 18 years of age
  • Have symptoms of vulva irritation and or abnormal discharge
  • Meet the clinical criteria for RVVC
  • Willing to participate in research

Exclusion criteria

Exclusion Criteria:

  1. Taking / injecting antibiotics in the past two weeks;
  2. A woman who intends to be pregnant, pregnant or lactating;
  3. Long term use of and ;
  4. ;
  5. There was no same fixed sexual partner (RSP) before and after treatment
  6. Patients with severe gastrointestinal diseases, including colorectal cancer, IBS, IBD, chronic or acute diarrhea, long-term constipation, etc., or receiving gastrointestinal surgery and abdominal surgery within one year, such as cholecystectomy;
  7. Patients with severe heart, liver and kidney dysfunction, mental diseases, infectious diseases, tumors, severe anemia, and severe diseases (such as rheumatoid arthritis, lupus erythematosus, etc.)
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
140 participants (actual)

Study arms

  • Active comparator
    Clotrimazole vaginal tablets

    Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months

    Drug: clotrimazole vaginal tablets

  • Active comparator
    Clotrimazole vaginal tablets+ Lactobacillus

    Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times + Lactobacillus Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months

    Drug: Clotrimazole vaginal tablets+ Lactobacillus

Interventions

  • Drugclotrimazole vaginal tablets

    Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months

    Also known as: clotrimazole vaginal tablets(Bayer)

  • DrugClotrimazole vaginal tablets+ Lactobacillus

    Intensive treatment: clotrimazole vaginal tablets 500mg, every 72 hours, three consecutive times Consolidation treatment: clotrimazole vaginal tablets 500mg, once a week, 6 months Human Reproductive Tract Active Lactobacillus,4g,qd ,3months

    Also known as: Clotrimazole vaginal tablets+ Lactobacillus(Umeta-mimi)

06

What researchers measure

Primary outcomes

  1. The cure rate of RVVC,

    The cure rate of RVVC,

    Time frame: 6 months

Secondary outcomes

  1. Recurrence of RVVC

    Recurrence of RVVC

    Time frame: 6 months

07

Study locations

1 site
  • Dept Obstetrics and Gynecology
    Shenzhen, Guangdong 518036, China
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jul 2020 to primary completion in Dec 2023, 41 months.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 5, 2021
First posted
Jan 7, 2021
StartActual
Jul 1, 2020
Primary completionActual
Dec 30, 2023
CompletionActual
Dec 30, 2023
Last update
Jun 12, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 12, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04699240
Lead sponsor
Peking University Shenzhen Hospital
Responsible party
Shangrong Fan (Profesor, Peking University Shenzhen Hospital) — Principal investigator
First posted
Jan 7, 2021
Start date
Jul 1, 2020
Primary completion
Dec 30, 2023
Completion
Dec 30, 2023
Last update
Jun 12, 2025

Study contacts

Shangrong Fan, M.D.
principal investigator · Peking University Shenzhen Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion